Project Grant R01CA307281
- Federal Grant Award Summary New York University School of Medicine received a $681,215 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning September 1, 2025 and concluding August 31, 2030. The project aims to develop artificial intelligence (AI)-enabled magnetic resonance (MR) imaging technology to support point-of-care prostate cancer detection at the population level. The research challenges conventional...
- Federal Grant Award Summary New York University School of Medicine received a $1.33 million Project Grant awarded August 12, 2025, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award funds the development of an artificial intelligence system designed to improve the diagnostic accuracy and cost-effectiveness of breast cancer screening by...
- Federal Grant Award Summary Yale University received a $519,592 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 15, 2026, with completion scheduled for May 31, 2031. The project focuses on developing and validating deep learning-derived magnetic resonance imaging (MRI) biomarkers for localized prostate cancer risk stratification. The research addresses limitations in current clinical assessment...
- Federal Grant Award Summary The National Cancer Institute (NCI), through its Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded The Leland Stanford Junior University a $660,346 Project Grant (July 1, 2026 – June 30, 2031) to develop artificial intelligence (AI) models that enable real-time prostate cancer detection during ultrasound-only biopsies. The research addresses a significant clinical gap: while approximately 1 million prostate biopsies are performed annually in the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $140,400 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) to develop artificial intelligence (AI)-based methods that integrate genomic and histopathologic data to advance precision cancer medicine. This Project Grant, awarded July 17, 2026, and scheduled for completion by June 30, 2028, funds research focused on creating multimodal, interpretable AI models that combine...
- Federal Grant Award Summary New York University School of Medicine received a $114,562 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The award, effective June 1, 2026 through May 31, 2028, funds development of an advanced diffusion-weighted magnetic resonance imaging (DWI) framework designed to overcome critical limitations in...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $640,956 Project Grant to the University of California, Los Angeles on May 15, 2026, with a completion date of April 30, 2031. This grant funds the development of an artificial intelligence (AI)-enhanced perfusion magnetic resonance imaging (MRI) tool designed to optimize yttrium-90 (Y90) microsphere distribution during radioembolization treatment of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant of $249,000 effective January 1, 2026 through December 31, 2028 under the Cancer Detection and Diagnosis Research program (CFDA 93.394). This award supports research to develop large-scale artificial intelligence (AI) and deep learning approaches to improve clinical outcomes in nuclear medicine imaging for cancer detection and diagnosis. The project addresses critical...
- Federal Project Grant Award Summary The National Cancer Institute (National Institutes of Health) awarded $761,691 to the University of California, Los Angeles on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a prospective randomized controlled trial evaluating the impact of artificial intelligence (AI) on breast cancer screening quality and effectiveness. The project, extending through May 31, 2031, represents the first real-world randomized...
- Federal Grant Award Summary The University of Florida Division of Sponsored Research received a $632,670 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective June 1, 2026 through May 31, 2031. The project, titled "Advancing Renal Mass Diagnosis and Management Through AI-Enhanced Decision Support Systems (RMM-DSS)," will deliver transformer-based vision-language models (VLMs) and decision...
New York University School of Medicine received a $700,171 Project Grant award dated July 16, 2026, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance clinically translatable deep learning (DL) models for prostate cancer detection on magnetic resonance imaging (MRI). The project, with a completion date of June 30, 2031, addresses critical gaps in prostate MRI interpretation by developing robust artificial intelligence solutions that improve diagnostic accuracy, consistency, and clinical reliability. The work encompasses three primary objectives: training a novel DL model on diverse imaging datasets to ensure consistent performance across varied scanners, protocols, and patient populations; incorporating uncertainty quantification and out-of-distribution detection mechanisms to enhance prediction reliability and provide actionable confidence measures for clinical decision-making; and evaluating the clinical utility of artificial intelligence assistance and confidence visualization through a multi-reader study. This research directly supports the National Cancer Institute's strategic focus on improving screening, early detection, and diagnostic techniques for cancer by reducing false positives and false negatives in prostate cancer detection, thereby decreasing unnecessary biopsies and improving patient management and surveillance outcomes.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $700.2k | 7/16/26 |